Recently Viewed
empty-cart

There are no Recent Items

Close
Login/Register

Close
Single User License Price USD 2000
Single User License Price INR 147380
Corporate User License Price USD 6000
Corporate User License Price INR 442140
Site License Price USD 4000
Site License Price INR 294760
Request a Quote

Report Title

Keratitis-Pipeline Review, H1 2017

Quote Request for License Type
License Type Price  
Single User License USD 2000
Site License USD 4000
Enterprise Wide License USD 6000
"Thanks for submitting the form. Our marketing team will connect back to you for the budget constraint."
Close
REQUEST A CUSTOMIZED RESEARCH

Report Title

Keratitis-Pipeline Review, H1 2017


Quote Request for License Type
License Type Price  
Single User License USD 2000
"Thanks for letting us know your requirement. Our research team will connect back to you for the bespoke requirement."
Close
REQUEST FOR SAMPLE REPORT

Report Title

Keratitis-Pipeline Review, H1 2017

"Thanks for submitting the form. The concerned team will send the sample report in the next 12 hours."
"Thank you for downloading the sample report."
Close

Keratitis-Pipeline Review, H1 2017



Executive Summary

Keratitis-Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Keratitis-Pipeline Review, H1 2017, provides an overview of the Keratitis (Ophthalmology) pipeline landscape.

Keratitis is an inflammation of the cornea. Symptoms include eye redness, eye pain, blurred vision, decreased vision and sensitivity to light. Risk factors include virus infections, injury, climatic condition and reduced immunity.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Keratitis-Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Keratitis (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Keratitis (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Keratitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase I, Preclinical and Discovery stages are 1, 1, 1, 8 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 4 molecules, respectively.

Keratitis (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Keratitis (Ophthalmology).

The pipeline guide reviews pipeline therapeutics for Keratitis (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Keratitis (Ophthalmology) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Keratitis (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Keratitis (Ophthalmology)

Reasons to buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Keratitis (Ophthalmology).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Keratitis (Ophthalmology) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Keratitis-Overview

Keratitis-Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Keratitis-Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Keratitis-Companies Involved in Therapeutics Development

Adamis Pharmaceuticals Corp

Dompe Farmaceutici SpA

Editas Medicine Inc

EyeGate Pharmaceuticals Inc

NanoViricides Inc

RegeneRx Biopharmaceuticals Inc

SIFI SpA

The Medicines Company

Keratitis-Drug Profiles

acyclovir sodium-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

B-2088-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

C-31G-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

cenegermin-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy for Herpetic Keratitis-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Herpecide-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IBN-1-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

JDE-004-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KU-55933-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PIM-45-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

polihexanide-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RGN-259-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule for Neurotrophic Keratitis-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit DNA Synthesis for Herpetic Keratitis-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptides for Bacterial Keratitis and Wounds-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

targocil-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tigecycline-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Keratitis-Dormant Projects

Keratitis-Discontinued Products

Keratitis-Product Development Milestones

Featured News & Press Releases

Dec 12, 2016: EMA Validates the Marketing Authorisation Application for Cenegermin Eye Drops (Oxervate) Submitted by Dompé

Jun 01, 2016: RegeneRx and Lee's Pharm Announce Acceleration of RGN-259 Development in China

May 27, 2016: SIFI announces the conclusion of Phase I clinical trial for the development of PHMB an orphan drug for the treatment of Acanthamoeba Keratitis, a rare ocular disease

Jan 12, 2016: NanoViricides CEO Dr. Eugene Seymour to Present at the Biotech Showcase in San Fransisco on Wednesday

Dec 02, 2015: rhNGF, the Dompe Biotech Molecule for the Treatment of Neurotrophic Keratitis, Receives Orphan Drug Designation from the European Medicines Agency

Oct 21, 2015: RegeneRx Updates on U.S. Ophthalmic Clinical Trials

Sep 30, 2015: RegeneRx Receives $500,000 Milestone Payment With Enrollment of First Patient in U.S. Phase 2b/3 Dry Eye Trial

Sep 21, 2015: RegeneRx Announces First Patient Enrolled in Phase 3 U.S. Neurotrophic Keratopathy Clinical Trial with RGN-259

Oct 20, 2014: RegeneRx Allowed to Proceed with Phase 3 Using RGN-259 Eye Drops for the Treatment of Neurotrophic Keratopathy

Sep 25, 2014: EuCornea: Dompe wins the “Best Poster Award” for its preliminary data concerning the use of rhNGF in the treatment of neurotrophic keratitis

Jul 23, 2014: Dompe announces the Food and Drug Administration has granted orphan drug designation to its rhNGF-based treatment for neurotrophic keratitis

Feb 14, 2013: Dompe Announces Enrollment Of First Patient In First International Clinical Trial Of rhNGF For Treatment Of Neurotrophic Keratitis

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

To know more information on Purchase by Section, please send a mail to sales@kenresearch.com

List of Figures

Number of Products under Development for Keratitis, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products by Top 10 Targets, H1 2017

Number of Products by Stage and Top 10 Targets, H1 2017

Number of Products by Mechanism of Actions, H1 2017

Number of Products by Stage and Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1 2017

List of Tables

Number of Products under Development for Keratitis, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Universities/Institutes, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Keratitis-Pipeline by Adamis Pharmaceuticals Corp, H1 2017

Keratitis-Pipeline by Dompe Farmaceutici SpA, H1 2017

Keratitis-Pipeline by Editas Medicine Inc, H1 2017

Keratitis-Pipeline by EyeGate Pharmaceuticals Inc, H1 2017

Keratitis-Pipeline by NanoViricides Inc, H1 2017

Keratitis-Pipeline by RegeneRx Biopharmaceuticals Inc, H1 2017

Keratitis-Pipeline by SIFI SpA, H1 2017

Keratitis-Pipeline by The Medicines Company, H1 2017

Keratitis-Dormant Projects, H1 2017

Keratitis-Discontinued Products, H1 2017

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Adamis Pharmaceuticals Corp, Dompe Farmaceutici SpA, Editas Medicine Inc, EyeGate Pharmaceuticals Inc, NanoViricides Inc, RegeneRx Biopharmaceuticals Inc, SIFI SpA, The Medicines Company

Keratitis Therapeutic Products under Development, Key Players in Keratitis Therapeutics, Keratitis Pipeline Overview, Keratitis Pipeline, Keratitis Pipeline Assessment


Related Products in vertical
red-whiteline

RECENT VIEWED REPORTS



Sign up for newsletter

Close
Apply For Job

  • Applicant Name
  • Job Function
  • Total Experience
  • Skills
  • Email ID
  • Notice Period
  • Current CTC & Expected CTC
  • Phone Number
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Your resume has been successfully received. HR will connect you within 14 days in case your resume gets shortlisted."
Close
Download Company Brochure

  • Name
  • Email
  • Company Name
  • Select Country*
  • Phone Number
  • Validation
  •   info-icon

    If validation code does not match, please refresh the page.

Close
Engage With Us

  • Name
  • Designation
  • Email
  • Phone No.
  • Company Name
  • Company URL
  • Select Country*
  • Requirements/ Comments
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Thanks for submitting the form. The concerned team will respond to your query in the next 8-12 hours"
Close

Compare

Expand